New Treatment Options for Diffuse Large B-Cell Lymphoma

AUTOIMMUNE THROMBOCYTOPENIA

Matthew J. Matasar, MD

Medical Oncologist

Regional Care Network Medical Site Director, MSK Bergen

Memorial Sloan Kettering Cancer Center, New York, USA

The interview was conducted by Prof. E.A. Osmanov, MD, PhD.

← Breakthrough Hemolysis as a Challenging Issue in Targeted Therapy of Paroxysmal Nocturnal Hemoglobinuria (Resolution of Expert Panel)
The Use of Checkpoint Inhibitors in Classical Hodgkin’s Lymphoma during the COVID-19 Pandemic (Pirogov Medical Center’s Experience) →